Davis Polk advised the several underwriters in connection with the follow-on offering of 6,571,428 shares of common stock of Natera, Inc. for total gross proceeds of approximately $230…
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…
Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…
Davis Polk advised the joint lead arrangers, joint bookrunners and the administrative agent in connection with a $1.5 billion unsecured revolving credit facility for NXP B.V. and NXP…
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …
Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of Natera, Inc. for total gross proceeds of approximately $100…
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of $300 million aggregate principal amount of floating-rate notes due 2022, …